Search Results

Showing 10 from 17 results

Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

Teva and Ignyta Announce Acquisition by Ignyta of Four Oncology R D Assets from Teva

Teva to Present Oncology Data at the 2016 American Society of Hematology ASH Annual Meeting Exposition

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti PD1 IL2 Therapy TEV 56278 in Immuno Oncology

Increasing Access to Medicines

Leveraging Teva s broad generics portfolio which includes most of the medicines on the World Health Organization s list of Essential Medicines we imagine new ways to bring more medicines to vulnerable populations One way we expand our reach is through our access to medicines programs

Spreading HOPE Teva s Work to Improve Global Access to Medicine

Dr David G Poplack is internationally recognized as a leader in the field of pediatric oncology who launched Global HOPE in 2016 from Texas Children s Hospital the largest children s hospital in the US

Women Teva Spotlight Tanisha D Hill